ClinicalTrials.gg
Not yet recruitingNCT06715332Updated Dec 4, 2024

Prospective Study of Using Novel Bipolar Scissors in Colorectal Endoscopic Submucosal Dissection

An interventional study of Colorectal ESD with SpydrBlade Flex in Colon Polyp and Colon Neoplasia, sponsored by Chinese University of Hong Kong. Not yet recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is an interventional, prospective, single-center study to evaluate the safety and effectiveness of a novel radiofrequency and microwave ablation flexible bipolar (SpydrBlade Flex, CREO Medical, UK) for colorectal ESD in patients with superficial colorectal neoplasia.

Read the detailed description

This is a prospective study with the following study Objectives:

  1. To evaluate the safety and effectiveness of a novel radiofrequency and microwave ablation flexible bipolar (SpydrBlade Flex, CREO Medical, UK) for colorectal ESD.
  2. To assess the impact of the procedure on patient recovery time and postoperative adverse event.

This study is an interventional, prospective, single-center study to evaluate the safety and effectiveness of a novel radiofrequency and microwave ablation flexible bipolar (SpydrBlade Flex, CREO Medical, UK) for colorectal ESD in patients with superficial colorectal neoplasia. Patients will undergo a ESD for superficial colorectal neoplasia. All ESD procedures will be performed by expert endoscopists with at least 50 prior experience of ESD.

02

Conditions studied

  • Colon Polyp
  • Colon Neoplasia

Keywords

  • Endoscopic submucosal dissection
03

In context

Colonic Polyps

377 studies on the registry are indexed under Colonic Polyps; 57 are open to participants now.

This study's planned enrollment of 30 is below the median of 274 across 250 interventional studies indexed under Colonic Polyps.

Browse Colonic Polyps studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,454 studies on the registry; 474 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (age ≥18 and ≤80 years-old)
  • Capability of understanding and complying with the study requirements, including signing the form.
  • Patients with colorectal superficial mucosal neoplasia (clinically adenoma or early intramucosal cancer), scheduled to undergo endoscopic submucosal dissection (ESD).

Exclusion criteria

Exclusion criteria:

  • Patients unable or unwilling to provide consent.
  • Patients with lesions unsuitable for ESD, including those suspicious of deep submucosal invasive cancer.
  • Patients with lesions involving the appendiceal orifice or ileocaecal valve.
  • Patients with significant cardiorespiratory comorbidities which may limit their ability to undertake monitored anesthesia for the procedure.
  • Poor performance status (Eastern Cooperation Oncology Group performance status ≥3).
  • Pregnant women or those planning pregnancy or breastfeeding women.
  • Uncorrectable coagulopathy defined by (INR) > 1.5 or count \< 50000/µl.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Endoscopic submucosal dissection with SpydrBlade Flex

    This group of patient would undergo endoscopic submucosal dissection with the use of the novel SpydrBlade Flex knife

    Device: Colorectal ESD with SpydrBlade Flex

Interventions

  • DeviceColorectal ESD with SpydrBlade Flex

    The allocated intervention would be performed under sedation or monitored anaesthesia by experienced endoscopists with at least 50 case experience of colon ESD. Colon ESD procedure would be performed as per described in the literature. After submucosal injection of solution to create a cushion, mucosal incision and submucosal dissection would be performed with the SydrBlade Flex. Submucosal plane dissection will be performed using the SpydrBlade Flex (BRF, cutting frequency 400kHz, power setting 35W). The exact resection strategy would be according to the endoscopists' preference, including different adjunctive techniques such as countertraction, tunnelling or pocket creation method. Upon completion of ESD, the resultant mucosal defect would be examined for any perforation or bleeding.

06

What researchers measure

Primary outcomes

  1. En-bloc resection rate

    Defined by complete macroscopic resection of the target neoplasia in one single specimen

    Time frame: 30 days

Secondary outcomes

  1. R0 resection rate

    Defined by histologically margin negative resection (Both horizontal and vertical margins)

    Time frame: 30 days

  2. Curative resection rate

    Defined by R0 resection and fulfilling existing histological curative resection criteria based on JGES guidelines

    Time frame: 30 days

  3. Adverse event rate

    Overall adverse event rate, according to ASGE lexicon

    Time frame: 30 days

  4. Rate of adverse event - hemorrhage

    Rate of intraprocedural and post procedural delayed hemorrhage

    Time frame: 30 days

  5. Rate of adverse event - perforation

    Rate of intraprocedural and post procedural delayed perforation

    Time frame: 30 days

  6. Rate of adverse event - post-ESD coagulation syndrome

    Defined by post-procedural abdominal pain and systemic inflammatory response

    Time frame: 30 days

Other outcomes

  1. Procedure time

    Duration of ESD

    Time frame: 1 day

  2. Device dysfunction

    Failure of device to continue the procedure

    Time frame: 1 day

  3. Need for change to other device

    Rate of changing to other ESD knife

    Time frame: 1 day

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06715332
Responsible party
Hon Chi Yip (Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Dec 4, 2024
Start date
Dec 8, 2024 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Dec 4, 2024

Study contacts

Hon Chi Yip, MBChB
Contact
hcyip@surgery.cuhk.edu.hk
35052627
Hon Chi Yip, MBChB
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion